CategoryDMT trials

What is the cancer risk with MS Disease-modifying treatments?

This question comes up time and again with MS treatments and probably is one of the most important negative selection choices secondary to PML for DMTs in MS. Every time a new drug is presented to the clinical community, the cancer stats are heavily scrutinised. For example, with ocrelizumab the greater number of breast cancers in the treated arm versus placebo impacted on who ultimately received...

Sipping siponimod and other SIPs

Go grab a cup of tea There are a group of drugs used in MS called Sphingosine-1-phosphate receptor modulators. These are known as “the imods”. Here, mod means modulator” and “i” means immune so the immune modulators have been shortened to “imod”. Some people get paid a load of cash to come up with drug names and they have come up with interesting ones...

Dieting.

I think I just wrote that I wouldnot write anything about diets, but I have been challenged You said “I know diet is seen as quackery on this blog. However it seams to be actually showing evidence of neuroprotection more than any of the drugs trialed so far”. I would argue not at all, ProfG may have talked about them, indeed he has just sent me a book on diets as has DoctorLove...

Difficulty is seeing Saving Nerves with Statins

Statins are agents used to reduce cholesterol. When used in a UK trial called MS-STAT they found that brain loss was slowed and suggested there was a benefical effect suggesting that nerves loss is inhibited by statins. “High-dose simvastatin reduced the annualised rate of whole-brain atrophy compared with placebo, and was well tolerated and safe”. So we now have MS-STAT2 on the go...

Another treatment for relapse

Wynn D, Goldstick L, Bauer W, Zhao E, Tarau E, Cohen JA, Robertson D, Miller A. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids. CNS Neurosci Ther. 2022 Jan 4. doi: 10.1111/cns.13789 Introduction: About 20%-35% of multiple sclerosis (MS)...

Top MS trials in the UK!

I have listed below in alphabetical order the most innovative and cutting edge clinical trials in the UK. They are almost exclusively Investigator/Institution led suggesting active interest from Clinicians and Scientists in developing targeted therapeutics for MS. For further details please visit clinicaltrials.gov. BTK (Bruton Tyyrosine Kinase) inhibitors Source: various pharmaceutical...

Will 2022 be the year AI-assisted MRI enters the management of pwMS?

Regular MRI is a key element in the follow-up of pwMS, particularly those on disease modifying treatment (DMT). Why? Because MRI is significantly more sensitive in detecting MS disease activity than counting relapses and measuring disability using the EDSS (Kurtzke’s Expanded Disability Status Scale). I’m quite precise here referring to the EDSS since other clinical instruments may be...

Blocked Drains an issue for MS. Part I

A decade ago we had the issue of CCSVI, where by it suggested that blocked veins was the cause of MS. People with MS got their veins expanded and claimed success without the need for a neuro. ProfK went straight into the argument to say “hang on a minute” Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ. No cerebrocervical venous congestion in patients with multiple sclerosis...

Autoimmune risks with alemtuzumab

Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Mult Scler. 2021 Dec 9:13524585211061335.  Does...

The hidden story

I would like to share with you an experience from one of our final year medical students, Molly Bond. Molly has been with our group for over an year now and has been shadowing the clinical team for this time. At the end of her attachment she wrote for the medical school a reflective piece about her experience. I’d like to share a portion of this with you. Her observations are insightful and...

Translate

Categories

Recent Posts

Recent Comments

Archives